Takeda's AI Drug Shows Superior Skin Clearance vs. Bristol-Myers

Takeda Pharmaceutical announced positive results from its LATITUDE Atlas study, a head-to-head trial pitting its experimental drug zasocitinib against Bristol-Myers Squibb's deucravacitinib (marketed as Sotyktu) for treating plaque psoriasis. The trial met all its primary and secondary goals.

Zasocitinib showed statistical superiority in achieving PASI 100, meaning complete skin clearance, at 16 weeks. It also beat the Bristol-Myers drug on other key measures, including PASI 90 (near-complete clearance) and a physician's assessment of clear skin.

The safety profile for zasocitinib was consistent with previous studies, with no new safety concerns identified. This is a critical factor for regulatory approval and future patient adoption.

Notably, zasocitinib was developed using artificial intelligence, showcasing a modern approach to drug discovery. Takeda is now preparing to submit the drug for approval in the U.S. and other markets starting this fiscal year.

This trial result is a significant competitive event. Bristol-Myers' Sotyktu is a leading oral treatment for psoriasis, so beating it head-to-head gives Takeda's drug a strong claim to best-in-class efficacy. This could reshape market share in a lucrative therapeutic area.

For Takeda, success here validates its investment in AI-driven R&D and could unlock a major new revenue stream. The company has previously estimated peak annual sales for zasocitinib could reach $3 to $6 billion if approved.

For Bristol-Myers Squibb, the results pose a direct threat to one of its newer growth products. While Sotyktu is established, a more effective competitor could slow its sales growth and impact long-term revenue projections.

Beyond these two companies, the success of an AI-developed drug reinforces a major industry trend. It could boost investor confidence in other biopharma firms leveraging AI, potentially affecting valuations across the sector.